Pharmaceutical Drugs Industry Overview

Ethical pharmaceuticals involve the manufacturing of drugs that are sold only with a doctor's prescription through a registered pharmacist. These drugs are controlled substances, and certain regulatory boards regulate their use. The main types of ethical pharmaceutical markets are lipid regulators, narcotic analgesics, ACE inhibitors, respiratory agents, diuretics, calcium antagonists, hormonal contraceptives, penicillin, vitamins, and minerals. Lipid regulators are substances that alter the metabolism of lipids. These are the nutrients found in a wide variety of vitamins, including prenatal formulations. Lipid regulators (HMG-CoA reductase inhibitors) are used to lower lipid levels and reduce the risk of cardiovascular events such as myocardial infarction and stroke. The distribution channels include hospital pharmacies, retail pharmacies, and others. The applications are hospitals, clinics, and pharmaceutical companies. The ethical pharmaceutical market research report is one of a series of new reports from The Business Research Company that provides ethical pharmaceutical market statistics, including ethical pharmaceutical industry global market size, regional shares, competitors with an ethical pharmaceutical market share, detailed ethical pharmaceutical market segments, market trends and opportunities, and any further data you may need to thrive in the ethical pharmaceutical industry. This ethical pharmaceutical market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global ethical pharmaceutical market size is expected to grow from $5.70 billion in 2022 to $6.38 billion in 2022 at a compound annual growth rate (CAGR) of 11.86%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The ethical pharmaceutical market size is expected to reach $10.03 billion in 2027 at a CAGR of 11.98%. The rising prevalence of chronic diseases is a primary driver propelling the ethical pharmaceutical market. Chronic conditions are those that endure for a year or longer and necessitate ongoing medical care. These conditions include diabetes, cancer, and heart disease. Ethical pharmaceutical drugs are commonly prescribed for the long-term treatment of chronic diseases, and this, in turn, increases the demand for ethical pharmaceuticals. For instance, according to the National Diabetes Statistics Report 2022 report published by the Centers for Disease Control and Prevention (CDC), a body of the US government, more than 130 million persons in the US have diabetes or prediabetes as per 2019 data. Further, according to the World Health Organization, a Switzerland-based health promotion agency, in 2021, chronic disease prevalence is expected to rise by 57% from 2020. According to figures from April 2021, these diseases account for 41 million deaths annually, or 71% of all fatalities worldwide. Therefore, the rising prevalence of chronic diseases is expected to propel the growth of the ethical pharmaceutical market. New technological innovations are gaining popularity in the ethical pharmaceutical market. Major companies operating in the market are introducing new technologies, such as Sugmadex, a new reversal agent. For instance, BDR Pharma an India-based pharma company and Varenyam Healthcare, an India-based pharma company, jointly launched the Sugmadex, a first-of-its-kind drug with the unique property of novel ?-cyclodextrin neuromuscular block (NMB) reversal properties. The use of the drug is expected to eliminate many of the shortcomings in current anaesthetic practice. Sugmadex is offered in single-dose vial sizes of 2 and 5 millilitres. In March 2022, Pfizer, a USA-based pharmaceutical company, acquired Arena Pharmaceuticals for $6.7 billion. Through this acquisition, Pfizer aims to benefit from bringing the pipeline of Arena Pharmaceuticals to the company’s inflammation and immunology therapeutic area and further improving developments to change the lives of those with immuno-inflammatory diseases. Arena Pharmaceuticals is a USA-based pharmaceutical company. Major players in the ethical pharmaceuticals market include Johnson & Johnson, GlaxoSmithKline PLC, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca PLC, The Bristol-Myers Squibb Company, Bayer AG, Mylan N.V., Acrux Limited, and Pfizer Inc. North America was the largest region in the ethical pharmaceutical market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ethical pharmaceutical market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the ethical pharmaceutical market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The ethical pharmaceutical market includes revenues earned by entities from pharmaceutical commodities and services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global ethical pharmaceuticals market is segmented - 1) By Type: Lipid Regulators, Narcotic Analgesics, ACE Inhibitors, Respiratory Agents, Diuretics, Calcium Antagonists, Hormonal Contraceptives, Penicillin, Vitamin 2) Minerals By Distribution Channel: Hospital Pharmacy, Retail Pharmacies, Other Distribution Channels 3) By Application: Hospitals And Clinics; Pharmaceutical Companies

Brain health supplements refer to supplements that improve brain function in healthy individuals. It also improves memory, motivation, creativity, attentiveness, and the overall cognitive performance of the brain.   The main products of brain health supplements are natural molecules, herbal extracts, vitamins, and minerals. Natural molecules refer to complex molecules composed largely of carbon atoms linked to other elements and/or carbon atoms. These supplements are available in the form of tablets, capsules, and liquids, which are distributed by supermarkets and hypermarkets, drug stores, and online. It is used for various applications such as memory enhancement, mood and depression management, attention and focus, longevity and anti-aging, sleep and recovery, and anxiety management. The brain health supplements market research report is one of a series of new reports from The Business Research Company that provides brain health supplements market statistics, including brain health supplements industry global market size, regional shares, competitors with a brain health supplements market share, detailed brain health supplements market segments, market trends and opportunities, and any further data you may need to thrive in the brain health supplements industry. This brain health supplements market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global brain health supplements market size is expected to grow from $8.61 billion in 2022 to $9.60 billion in 2023, at a compound annual growth rate (CAGR) of 11.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The brain health supplements market is expected to grow to $14.61 billion in 2027 at a CAGR of 11.1%. An increase in the prevalence of brain diseases is expected to propel the growth of the brain health supplements market going forward. Brain diseases refer to a disability that affects the brain and is considered a disorder. Essential nutrient supplementation, such as long-chain polyunsaturated fatty acids, vitamin E, and mineral elements, may reduce inflammation, improve antioxidative defense, and reduce the risk. For instance, in October 2022, according to a report released by the BrightFocus Foundation, a US-based non-profit organization, it is expected that about 500k new instances of Alzheimer's disease would be identified in the United States every year. Alzheimer's dementia affects 5% of those aged 65 to 74, 13% of those aged 75 to 84, and 33% of those aged 85 and older. Therefore, an increase in the prevalence of brain diseases is driving the growth of the brain health supplements market. Product innovation is a key trend gaining popularity in the brain health supplements market. Major companies operating in the brain health supplements market are developing innovative products to sustain their position in the brain health supplements market. For instance, in March 2022, Cosmos Holdings, a US-based pharmaceutical company, launched Proprietary Sky Premium Life Brainlit, an advanced formula to maintain and enhance brain function. Alzheimer's disease and other kinds of dementia, Parkinson's disease, depression, and anxiety have all been on the rise in recent years, despite a substantial unmet demand for effective treatment alternatives. The Brainlit supplement is created with the best quality raw ingredients and includes Ginkgo biloba, glutamine, L-tyrosine, and other vitamins and minerals important for brain function. In September 2021, HAVN Life Sciences, a Canada-based biotechnology company, acquired Bennett's Choice for an undisclosed amount. This acquisition adds a fresh and exceptional collection of patented formulas to our line of natural health products. Bennett's Choice is a Canada-based supplement development company. Major players in the brain health supplements market are Accelerated Intelligence Inc., AlternaScript LLC, Aurobindo Pharma Limited (Natroll LLC), HVMN Inc., Intelligent Labs, KeyView Labs Inc., Liquid Health Inc., Natural Factors Nutritional Products Ltd., NOW Foods, Onnit Labs LLC, Peak Nootropics, Purelife Bioscience Co. Ltd., Quincy Bioscience LLC, Reckitt Benckiser Group plc, Teva Pharmaceutical Industries Ltd., and Vital Basics Inc. North America was the largest region in the brain health supplements market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the brain health supplements report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the brain health supplements market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The brain health supplements market consists of sales of B vitamins, caffeine, and L-theanine products. Values in this market are ‘nutraceuticals’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.   The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global brain health supplements market is segmented - 1) By Product: Natural Molecules, Herbal Extract, Vitamins, and Minerals 2) By Supplement Form: Tablets, Capsules, Liquid 3) By Distribution: Supermarket and Hypermarket, Drug Store, Online 4) By Application: Memory Enhancement, Mood and Depression, Attention and Focus, Longevity and Anti-Aging, Sleep and Recovery, Anxiety

Effervescent tablets are the solid dosage form of tablets that are engineered to break down faster when they come into contact with water by releasing carbon dioxide. The tablets entirely disintegrate in a matter of minutes, releasing the medication into solution. The main products of effervescent tablets are medication and supplements. Medication refers to any drug, medical preparation, or remedy used to treat biological abnormalities and illnesses. The methods involved in the preparation of effervescent tablets are dry methods and wet granulation, which are used for indications including diuretics, pain management, gastric disorders, respiratory diseases, and others. It is applied to dental products, dietary supplements, pharmaceuticals, and others by various end-users such as hospitals, specialty clinics, home care, and others. The effervescent tablets market research report is one of a series of new reports from The Business Research Company that provides effervescent tablets market statistics, including effervescent tablets industry global market size, regional shares, competitors with an effervescent tablets market share, detailed effervescent tablets market segments, market trends and opportunities, and any further data you may need to thrive in the effervescent tablets industry. This effervescent tablets market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global effervescent tablets market size is expected to grow from $30.52 billion in 2022 to $33.38 billion in 2023 at a compound annual growth rate (CAGR) of 9.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The effervescent tablets market is expected to grow to $47.22 billion in 2027 at a CAGR of 9.1%. The high prevalence rate of chronic diseases is expected to propel the growth of the effervescent tablets market going forward. Chronic disease often lasts for three months or longer and may worsen with time. The most prevalent chronic diseases are cancer, heart disease, stroke, diabetes, and arthritis. Effervescent tablets are used in the treatment of chronic illnesses such as diabetes, cancer, and heart disease as a potent antioxidant that boosts blood antioxidant levels and helps reduce the risk of chronic diseases. For instance, in 2021, according to the World Health Organization, a Switzerland-based government agency responsible for international public health, cardiovascular diseases are the leading cause of death worldwide, taking an estimated 17.9 million lives each year. Further, in September 2020, according to Imperial College London, a UK-based public research university, seven out of ten deaths worldwide are believed to be caused by chronic diseases, which are responsible for almost 41 million deaths annually. Therefore, the high prevalence rate of chronic diseases is driving the growth of the effervescent tablets market. Technological advancements are a key trend gaining popularity in the effervescent tablet market. Major players are concentrating on creating innovative manufacturing technologies to sustain their position in the effervescent tablet market. For instance, in April 2022, Health Innovations Ltd., a UK-based healthcare supplement manufacturing company, launched EfferShield technology. EfferShield is a patent-mated technology used for effervescent pills and powders. It is available in single-use pouches and stick-pack packaging, so consumers have more flexible and convenient packaging options with possibilities for recycling and at-home composting. In March 2020, DCC plc, an Ireland-based sales, and marketing service company, acquired Amerilab Technologies Inc for $85 million. With this acquisition, DCC plc expands its effervescent nutritional products manufacturing portfolio and product reach into the United States and related countries. Amerilab Technologies Inc. is a US-based contract manufacturing company specializing in the manufacture of effervescent nutritional products in powder and tablet forms. Major players in the effervescent tablet market are Bayer AG, Hermes Arzneimittel GmbH, GSK plc, Reckitt Benckiser Group plc, Bristol-Myers Squibb Company, Bliss GVS Pharma Limited, Herbalife International Inc., Amerilab Technologies Inc., Pfizer Inc., Novartis AG, Perrigo Company plc, Chiesi Farmaceutici SpA, SG Biopharm Pvt Ltd., Advanced Enzyme technologies Limited, Vovantis Laboratories Pvt Ltd., Nutrilo GmbH, Tower Laboratories, and Novartis North America was the largest region in the effervescent tablets market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the effervescent tablet report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the effervescent tablet market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The effervescent tablet market consists of sales of prescription-based tablets and daily-used tablets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global effervescent tablet market is segmented - 1) By Product: Medication, Supplements 2) By Methods: Dry Methods, Wet Granulation 3) By Indication: Diuretics, Pain Management, Gastric Disorders, Respiratory Diseases, Other Indications 4) By Application: Dental Products, Dietary Supplements, Pharmaceuticals, Other Applications 5) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Empty capsules are a stable shell that encapsulates pharmaceuticals or medication combinations in an enclosed container. The empty capsules can be used to store herbs, powders, and medications. The main types of empty capsules are gelatin and non-gelatin capsules. Gelatin capsules refer to capsules made of gelatin, which is an animal protein used to make capsules that can deliver precise amounts of product. The functionality of the capsules includes immediate-release, sustained-release, and delayed-release capsules. These are used in several applications, such as antibiotics, antibacterial drugs, dietary supplements, antacid and antiflatulent preparations, antianemic preparations, anti-inflammatory drugs, cardiovascular therapy drugs, cough and cold drug preparations, and others, and by various end-users, including the pharmaceutical industry, the nutraceutical industry, the cosmetic industry, and research laboratories.   The empty capsules market research report is one of a series of new reports from The Business Research Company that provides empty capsules market statistics, including empty capsules industry global market size, regional shares, competitors with an empty capsules market share, detailed empty capsules market segments, market trends and opportunities, and any further data you may need to thrive in the empty capsules industry. This empty capsules market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global empty capsules market size is expected to grow from $2.71 billion in 2022 to $2.96 billion in 2023 at a compound annual growth rate (CAGR) of 9.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The empty capsules market is expected to grow to $4.15 billion in 2027 at a CAGR of 8.9%. An increase in the prevalence of chronic diseases is expected to propel the growth of the empty capsules market going forward. Chronic disease often lasts for three months or longer and may worsen with time. The most prevalent chronic diseases are cancer, heart disease, stroke, diabetes, and arthritis. Empty capsules are used to deliver a variety of drugs without changing their formulation; these capsules are designed to ensure proper drug delivery without interfering with any drug formulation. For instance, in September 2020, according to a study report issued by the American Action Forum, chronic illness frequency and expenses are increasing in the United States. Chronic illness is anticipated to continue increasing as the incidence of illness among children and young people increases. Chronic illness is a significant healthcare issue since it costs the US $3.7 trillion annually, or about 19.6% of the GDP, and is rising. Therefore, an increase in the prevalence of chronic diseases is driving the growth of the empty capsules market. Product innovations are a key trend gaining popularity in the empty capsules market. Major companies operating in empty capsules are developing new products to strengthen their position in the market. For example, in October 2021, CapsCanada, a Canada-based pharmaceutical company that develops empty capsules launched a new liquid-filled hard capsule manufacturing service. This aims for the development of full-scale production, which is less complex and capital-intensive than manufacturing soft gels, with filling equipment available at all scales, from benchtop to production. In August 2022, Catalent, a US-based pharma company, acquired Metrics Contract Services for $475 million. Through this acquisition, Catalent wants to expand its high-potency capabilities, oral product development, and manufacturing capacity. Metrics Contract Services is a North Carolina-based pharma development company operating in empty hard gelatin capsules. Major players in the empty capsules market are ACG Group, CapsCanada Corporation, HealthCaps India Limited, Natural Capsules Ltd., Bright Pharma Caps Inc., Suheung Co., Ltd., Roxlor L.C., Lonza Group AG, Capsugel, Goerlich Pharma GmbH, Qualicaps Inc., Comed Chemicals Limited, Wuhan Carma Technology Co., Ltd., Nectar Lifesciences Ltd., and Erawat Pharma Limited. North America was the largest region in the empty capsules market in 2022. The regions covered in the report on empty capsules are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the empty capsules market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The empty capsules market consists of sales of hard gelatin capsules, soft gelatin capsules, fish gelatin capsules, starch capsules, pullulan capsules, polyvinl acetate (pva) capsules, and liquid-filled hard capsules (LFHC). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.   The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global empty capsules market is segmented - 1) By Type: Gelatin Capsules, Non-Gelatin Capsules 2) By Functionality: Immediate-release Capsules, Sustained-release Capsules, Delayed-release Capsules 3) By Application: Antibiotic and Antibacterial Drugs, Dietary Supplements, Antacid and Antiflatulent Preparations, Antianemic Preparations, Anti-inflammatory Drugs, Cardiovascular Therapy Drugs, Cough and Cold Drug Preparations, Other Therapeutic Applications 4) By End-User: Pharmaceutical Industry, Nutraceutical Industry, Cosmetic Industry, Research Laboratories

Soft gelatin capsules, also known as softgels or soft elastic capsules, are capsules that dissolve faster than hard gelatin capsules and are used to carry medicine in liquid or powder form. It is used to deliver pharmaceuticals and a variety of nutritional supplements, including omega-3 fish oils.   The main types of soft gel capsules are gelatin or animal-based, and non-animal based. Gelatin or animal-based refers to cattle and pig connective tissues, boiling, broken bones, and decomposing animal hides that are used to make gelatin. The various manufacturers are pharmaceutical companies, nutraceutical companies, cosmeceutical companies, contract manufacturing organizations, and manufacturers of softgel capsules that are used in antacid and anti-flatulent preparations, anti-anemic preparations, anti-inflammatory drugs, antibiotics, and antibacterial drugs, cough and cold preparations, health supplements, vitamin D dietary supplements, and pregnancy. The soft-gel capsules market research report is one of a series of new reports from The Business Research Company that provides soft-gel capsules market statistics, including soft-gel capsules industry global market size, regional shares, competitors with a soft-gel capsules market share, detailed soft-gel capsules market segments, market trends and opportunities, and any further data you may need to thrive in the soft-gel capsules industry. This soft-gel capsule market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global softgel capsules market size is expected to grow from $7.20 billion in 2022 to $7.75 billion in 2023 at a compound annual growth rate (CAGR) of 7.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The softgel capsules market is expected to grow to $10.27 billion in 2027 at a CAGR of 7.3%. The rising prevalence of chronic ailments such as cardiovascular diseases is expected to drive the growth of the soft gel capsules market going forward. Chronic diseases refer to ailments that persist for a year or longer, such as cancer, heart disease, stroke, diabetes, cancer, and arthritis. These are the most common chronic illnesses, which can be controlled but not cured and require ongoing nutrition and medical care. Soft gel capsules provide the nutritional supplements required for chronic patients; as a result, the rising prevalence of chronic ailments increases the demand for soft gel capsules. For instance, in September 2020, according to a study report issued by the American Action Forum, chronic illness frequency and expenses are increasing in the United States. Chronic illness is anticipated to continue increasing as the incidence of illness among children and young people increases. Chronic illness is a significant healthcare issue since it costs the US $3.7 trillion annually, or about 19.6% of the GDP, and is rising. Therefore, the rising prevalence of chronic ailments such as cardiovascular diseases will drive the soft gel capsules market. Technological advancements are a key trend gaining popularity in the soft gel capsules market. Major companies operating in the soft gel capsules market are focused on developing new products with the latest technologies to sustain their position in the market. For instance, in November 2020, Roquette, a France-based provider of plant-based ingredients and pharmaceutical excipients, launched the pharmaceutical-grade solution LYCAGEL for a vegetarian soft gel capsule formulation developed with a pea starch technology. The new capsule formulation contains salt, NEOSORB sorbitol, a plant-based component utilized for nutraceutical purposes, and carrageenan, a setting agent found in marine macroalgae. The new product offers notable capsule strength, seal integrity, a short drying time without stickiness, quick disintegration, no cross-linking, and a processing temperature suitable for higher temperatures. In August 2021, Catalent, Inc., a US-based provider of development sciences and manufacturer of medicines, acquired Bettera Holdings, LLC, for $1 billion. Through this acquisition, Catalent, Inc. expects to accelerate the growth of its global softgel and oral dose formulation and manufacturing businesses to provide consumer health innovators with unrivalled choice, formulation expertise, and high-quality, scalable manufacturing solutions to help bring new products to market. Bettera Holdings LLC is a US-based provider of consumer-preferred products for nutraceutical, functional, and botanical ingredients, including soft gel capsules. Major players in the softgel capsules market are Catalent Inc., Eurocaps Ltd., Capsugel Healthcare Ltd., Aenova Group GmbH, Sirio Pharma Co. Ltd. (SIRIO), Procaps Laboratories, Captek Softgel International Inc., Fuji Capsule Co. Ltd., Hunan ER-KANG Pharmaceutical Co. Ltd., Patheon, Curtis Health Caps, Delpharm Evreux, Estrellas Life Sciences Pvt. Ltd., Elnova Pharma, and Soft Gel Technologies Inc. North America was the largest region in the soft gel capsules market in 2022. The regions covered in the soft gel capsules report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the soft gel capsules market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The soft gel capsules market consists of sales of liquid or semisolid-filled capsules, chewables, suckers, twist-offs, and meltable capsules. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global softgel capsules market is segmented - 1) By Type: Gelatin or Animal Based, Non-Animal Based 2) By Manufacturers: Pharmaceutical Companies, Nutraceutical Companies, Cosmetic Companies, Contract Manufacturing Organizations, Softgel Capsules 3) By Application: Antacid And Anti-Flatulent Preparations, Anti-Anemic Preparations, Anti-Inflammatory Drugs, Antibiotic And Antibacterial Drugs, Cough And Cold Preparations, Health Supplement, Vitamin And Dietary Supplement, Pregnancy

Pharmaceutical filtration is a technique that removes solid particulate matter from a fluid, which can be either liquid or gas, by utilising a porous medium. It is used in pharmaceutical production sectors to remove pollutants like as particulate matter and bacteria from solids, air, liquids, and gases. The main products of the pharmaceutical filtration are membrane filters, prefilters, and depth media, single-use systems, cartridges and capsules, filter holders, and filtration accessories. Membrane filters refer to the flow of fluids or gases while preventing the passage of particles and microorganisms. The various techniques used are microfiltration, ultrafiltration, crossflow filtration, and nanofiltration, which involve scale of operations functions such as manufacturing scale, pilot scale, and research and development scale. The various applications include final product processing, raw material filtration, bioburden testing, cell separation, water purification, and air purification. The pharmaceutical filtration market research report is one of a series of new reports from The Business Research Company that provides pharmaceutical filtration market statistics, including pharmaceutical filtration industry global market size, regional shares, competitors with a pharmaceutical filtration market share, detailed pharmaceutical filtration market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical filtration industry. This pharmaceutical filtration market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global pharmaceutical filtration market size is expected to grow from $6.56 billion in 2022 to $6.96 billion in 2023 at a compound annual growth rate (CAGR) of 6.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The pharmaceutical filtration market is expected to reach $8.52 billion in 2027 at a CAGR of 5.2%. An increase in demand for generic drugs is expected to propel the growth of the pharmaceutical filtration market going forward. Generic pharmaceuticals are medications designed to be the same as an existing approved brand-name drug. Pharmaceutical filtration is used in the process of generic drugs by removing solid particulate matter from a fluid, which can be either liquid or gas, using a porous medium. For instance, according to the India Brand Equity Foundation, an India-based export promotion agency, India is the world's largest supplier of generic drugs; as of June 2022, the Indian pharmaceutical sector supplies more than 40% of generic demand in the United States and 25% of all pharmaceuticals in the United Kingdom. Furthermore, according to IMS Health, a US-based healthcare technology company, generic drugs would dominate prescription drug usage in the US, with demand rising from 88% to 92% of all prescription drugs sold in the US by 2020. Therefore, the increase in demand for generic drugs is driving the growth of the pharmaceutical filtration market. Product innovation is a key trend gaining popularity in the pharmaceutical filtration market. Many companies operating in the pharmaceutical filtration market are developing new products with advanced methods of filtration such as high-volume filtration plates to strengthen their position in the pharmaceutical filtration market. For instance, in November 2021, ANDRITZ, an Austria-based company operating in pharmaceutical filtration launched Nutrion, an innovative vacuum filter for the pharma and food industries. This innovative filter consists of improved features to eliminate the risk of contamination by taking filter-cloth installation to the next level and eliminating dirt traps and reduces downtime for cloth changes. In November 2021, Donaldson Company, a US-based vertically integrated filtration company, acquired Solaris Biotechnology for €41 million (USD46.3 million). Through this acquisition, Donaldson Company aims to strengthen its presence in the life sciences market. Solaris Biotechnology is an Italy-based designer and manufacturer of bioprocessing equipment, including fermenters, bioreactors, and tangential flow filtration systems. Major players in the pharmaceutical filtration market are 3M Health Care, Danaher Corporation, Amazon Filters Ltd., Eaton Corporation plc, GE Healthcare, Graver Technologies LLC, Meissner Filtration Products, Merck & Co., Inc., Parker Bioscience Filtration, Sartorius AG, Repligen, Porvair Plc, Alfa Laval AB, Corning Incorporated, and Thermo Fisher Scientific. North America was the largest region in the pharmaceutical filtration market in 2022. The regions covered in the pharmaceutical filtration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the pharmaceutical filtration market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and the USA. The pharmaceutical filtration market includes revenues earned by entities by providing reverse osmosis, sterile filtration, chromatography, sterile sampling and nanofiltration. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global pharmaceutical filtration market is segmented - 1) By Product: Membrane filters, Prefilters and depth media, Single-use systems, Cartridges and capsules, Filter holders, Filtration accessories, Other Products 2) By Technique: Microfiltration, Ultrafiltration, Crossflow filtration, Nanofiltration, Other Techniques 3) By Scale of Operation: Manufacturing scale, Pilot-scale, Research and development scale 4) By Application: Final product processing, Raw material filtration, Bioburden testing, Cell separation, Water purification, Air purification

Meningococcal vaccinations are vaccines that protect against meningococcal meningitis, an infection with the bacterium Neisseria meningitides that leads to inflammation of the tissues that surround the brain and spinal cord. The main types of meningococcal vaccines are meningococcal conjugate vaccine, polysaccharide vaccine, and subcapsular vaccine. Meningococcal conjugate vaccine refers to a compound made up of a polysaccharide antigen fused (conjugated) to a carrier molecule. The different serotypes include Men ACWY, Men B/Bc, and Men C, given to various age groups such as infants, children, adolescents, young adults, and adults, and distributed by pharmacies, community clinics, public health agencies, and others. These are used by various end-users, such as hospitals, research institutions, and academic institutes. The meningococcal vaccines market research report is one of a series of new reports from The Business Research Company that provides meningococcal vaccines market statistics, including the meningococcal vaccines industry's global market size, regional shares, competitors with a meningococcal vaccines market share, detailed meningococcal vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the meningococcal vaccines industry. The meningococcal vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global meningococcal vaccines market size is expected to grow from $3.21 billion in 2022 to $3.53 billion in 2023 at a compound annual growth rate (CAGR) of 10%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The meningococcal vaccines market size is expected to grow to $5.09 billion in 2027 at a CAGR of 9.6%. An increase in healthcare spending is expected to propel the growth of the meningococcal vaccine market going forward. Healthcare refers to a residential care institution, nursing facility, intermediate care facility for people with mental illnesses, or intermediate care facility for people with mental retardation. The high expense of new vaccine generations compared to their predecessors has become a key factor in discussions about whether the benefits of the new vaccinations justify their prices. Assessing the complete social and economic advantages of vaccination is becoming an increasingly important area of investigation in the literature on valuing vaccination. For instance, in May 2022, according to an article published by the American Medical Association, a US-based professional association and lobbying group of physicians and medical students, healthcare spending in the United States had risen by 9.7% to $4.1 trillion, or $12,530 per person. This pace of growth is significantly higher than 2019's (4.3%). Therefore, an increase in healthcare spending is driving the growth of the meningococcal vaccine market. Product innovation is a key trend in the meningococcal vaccine market. Major players operating in the meningococcal vaccines market are creating innovative new items using cutting-edge technology to maintain their position in the meningococcal vaccines market. For instance, in April 2020, Sanofi Pasteur Inc., a France-based life-protecting vaccines company, received Food and Drug Administration (FDA) approval for the usage of menquadfi by those who are at least 2 years old. Menquadfi helps to prevent the spread of invasive meningococcal illnesses (including meningitis) caused by the bacteria N meningitides serogroups A, C, W, and Y. The initial and single quadrivalent meningococcal strains are called MenQuadfi vaccinations. It employs tetanus toxoid as a protein carrier and is accessible in a ready-to-use liquid format, eliminating the need for healthcare personnel to reconstitute the vaccine. In August 2022, GlaxoSmithKline plc, a UK-based pharmaceutical and biotechnology company, acquired Affinivax Inc. for $3.3 billion. The acquisition of Affinivax is consistent with GSK's aim of establishing a robust portfolio of specialty medicines and vaccines. Affinivax, Inc., is a US-based next-generation vaccine technology company operating in the meningococcal vaccines market. Major players in the meningococcal vaccines market are Pfizer Inc., Novartis AG, Sanofi S.A., Serum Institute of India Pvt. Ltd., GlaxoSmithKline plc, Merck & Co., Inc., Incepta Pharmaceuticals Ltd., Bio-Med Limited, Walvax Biotechnology Co., Ltd., Bio-Manguinhos, Hualan Biological Engineering Inc., JN-International Medical Corporation, Johnson & Johnson, AstraZeneca plc, and Bavarian Nordic A/S. North America was the largest region in the meningococcal vaccines market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the meningococcal vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The meningococcal vaccines market consists of sales of conjugate vaccines, combination vaccines, serogroup B vaccine products, and other types. Values in this market are ‘pharmaceuticals’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global meningococcal vaccines market is segmented - 1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine 2) By Serotype: Men Acwy, Men B/Bc, Men C 3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults 4) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Channels 5) By End user: Hospitals, Research, Academic Institutes

Local anesthesia drugs are a type of pain control used during minor procedures to numb a small area where the pain is likely to occur. These drugs are used as local anesthetics to suppress pain receptors known as nociceptors, blocking them from sending pain impulses to the brain. The main types of local anesthesia drugs are bupivacaine, lidocaine, benzocaine, ropivacaine, prilocaine, chloroprocaine, and others. Bupivacaine is a local anesthetic C18H28N2O that is like lidocaine in its action but is longer acting. The modes of administration are injectable and surface anesthetics, which are distributed through hospital pharmacies, pharmacy stores, and other channels. The local anesthesia drugs market research report is one of a series of new reports from The Business Research Company that provides local anesthesia drugs market statistics, including local anesthesia drugs industry global market size, regional shares, competitors with a local anesthesia drugs market share, detailed local anesthesia drugs market segments, market trends and opportunities, and any further data you may need to thrive in the local anesthesia drugs industry. This local anesthesia drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global local anesthesia drugs market size is expected to grow from $4.05 billion in 2022 to $4.30 billion in 2023 at a compound annual growth rate (CAGR) of 6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The local anesthesia drugs market size is expected to grow to $5.23 billion in 2027 at a compound annual growth rate (CAGR) of 5%. The increase in number of surgeries is expected to propel the local anaesthesia drugs market forward. A medical speciality known as surgery deals with the physical and mechanical treatment of wounds, illnesses, and other ailments. Surgeries are increasing in the world due to accidents and chronic ailments such as cardiovascular diseases, cancers, and orthopaedic disorders. As a result, the increasing number of surgeries increases the demand for local anaesthesia drugs because those drugs are commonly used in surgeries. For instance, according to the National Library of Medicine, a US-based organization for biotechnology information, the number of cardiovascular surgeries is predicted to increase consistently to reach a demand of 15,501 cases in 2040, with an increase of 46.5 %. This growth rate is substantially higher than 2019's (4.3%). Therefore, the increasing number of surgeries drives the local anaesthesia drugs market. Product innovation is a key trend in the local anaesthesia drugs market. Major companies operating in the local anaesthesia drugs market focus on developing new product solutions to strengthen their position. For instance, in December 2021, Hikma Pharmaceuticals PLC, a UK-based company operating in local anaesthesia drugs, introduced the Bupivacaine HCl Injection in 10mL and 30mL doses with improvements like 0.25%, 0.5%, and 0.75%. Bupivacaine HCl Injection is recommended for adults to produce local or regional anaesthesia or analgesia for surgical, dental, and oral surgery operations, as well as diagnostic and treatments and obstetrical procedures. In July 2021, Septodont, an India-based pharmaceutical dentistry company, acquired Utlracain for an undisclosed amount. Through this acquisition, Septodont’s existing dental portfolio will allow them to strengthen the value proposition they bring to the customers through a broader range of products and solutions. Ultracain is a France-based company operating in local anaesthesia drugs. Major players in the local anesthesia drugs market are Hikma Pharmaceuticals PLC, Fresenius SE & Co. KGaA, Glenmark Pharmaceutical Limited, B. Braun Melsulgen AG, Pacira BioSciences Inc., Pfizer Inc., Septodont, Teva Pharmaceutical Industries Limited, Aspen Pharmacare Holdings Limited, Novartis Inc., Sagent Pharmaceutical, Mylan N.V., Advanced Pharma Inc., Akorn Operating Company LLC, and Endo International plc. North America was the largest region in the local anesthesia drugs market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the local anesthesia drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the local anesthesia drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The local anesthesia drugs market consists of sales of propofol, etomidate, ketamine, and other types. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global local anesthesia drugs market is segmented - 1) By Type: Bupivacaine, Lidocaine, Benzocaine, Ropivacaine, Prilocaine, Chloroprocaine, and Other Types 2) By Mode of Administration: Injectable, Surface Anesthetic 3) By Distribution Channel: Hospital Pharmacy, Pharmacy Stores, Other Channels